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ABSTRACT
Introduction: The aim of this study was to
describe factors associated with initiating a
biologic as monotherapy vs in combination
with a conventional disease-modifying
antirheumatic drug (DMARD) in biologic-naive
patients with rheumatoid arthritis (RA) enrolled
in the Corrona registry.
Methods: First biologic initiations were
classified as monotherapy (Bio MT) or
combination therapy (Bio CMB). Baseline
demographic and clinical characteristics were
evaluated. Odds ratios (OR) based on mixed
effects regression models estimated the
association of covariates and use of
monotherapy. Median odds ratios (MOR)
based on estimated physician random effects
quantified variation in individual physician use
of monotherapy.
Results: Between October 2001 and April 2012,
3,923 previously biologic-naive patients
initiated biologic therapy, of which 19.1 %
initiated as monotherapy. Baseline
characteristics of patients initiating Bio MT
and Bio CMB were similar for age, sex,
duration of RA, and clinical disease activity
index. Significantly higher proportions of Bio
CMB initiators had prior conventional DMARD
(97.23 vs 85.60 %; P\0.01) and methotrexate
(MTX) use (91.68 vs 71.87 %; P\0.01)
compared with Bio MT initiators. Variation in
individual physician use of monotherapy [MOR
1.89; 95 % confidence interval (CI), 1.66–2.23]
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and use of biologics approved by the United
States Food and Drug Administration for
monotherapy (OR 1.47; 95 % CI, 1.20–1.81)
significantly influenced the odds of initiating
Bio MT. Patient history of hepatic disease,
neutropenia, and malignancy were associated
with increased odds of being prescribed Bio MT.
Conclusion: In addition to regulatory approval
for monotherapy and specific pre-existing
comorbidities, significant variation in
physician use of monotherapy was associated
with increased likelihood of initiating Bio MT,
independent of patient factors.
Keywords: Biologic agents; Biologic
monotherapy; Disease-modifying
antirheumatic drugs; Prescribing patterns;
Registry; Rheumatoid arthritis
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disease manifesting as joint
inflammation that, if left untreated, eventually
leads to joint damage, destruction, and disability.
International task forces recommend
conventional disease-modifying antirheumatic
drugs (DMARDs) as first-line therapy in patients
with RA, which should be started as soon as the
diagnosis has been made with the goal of
achieving remission or low disease activity [1,
2]. However, a proportion of patients fail to
respond to conventional DMARDs. In addition, a
number of patients may not be able to tolerate
conventional DMARDs due to medication
toxicity, contraindicating comorbidities, or
interactions with other medications [3]. In such
patients, treatment with a biologic DMARD as
monotherapy may provide clinical benefit while
sparing the patient from undesirable side effects
due to conventional DMARDs [4].
Five classes of target-specific biologic
DMARDs are currently available for patients
with RA who do not respond or cannot
tolerate conventional DMARDs. These include
anti–tumor necrosis factor (TNF) agents
(adalimumab, certolizumab pegol, etanercept,
golimumab, and infliximab), an anti-interleukin
(IL)-6 receptor antibody (tocilizumab), an
anti-CD20 antibody (rituximab), an IL-1
receptor antagonist (anakinra), and a T cell
costimulation modulator (abatacept). In the
United States and Europe, most biologics—with
the exception of rituximab, infliximab,
and golimumab—are approved for use as
monotherapy in patients with RA. In addition,
the oral small molecule Janus kinase inhibitor
(tofacitinib) may be used as monotherapy or in
combination with methotrexate (MTX) or other
conventional DMARDs.
Numerous studies of patients who have an
inadequate response to DMARDs have
demonstrated that biologic agents, such as
anti-TNFs, offer higher levels of disease
control, better symptomatic improvement,
and possibly improved prevention of
radiographic progression when prescribed in
combination with MTX than when prescribed
as monotherapy [5–8]. On the other hand, in a
single study of patients with an inadequate
response to MTX, tocilizumab demonstrated
similar clinical efficacy when prescribed as
either monotherapy or in combination with
MTX [9]. In addition, real-world data derived
from registries and claims database studies in
the United States and Europe have reported that
12–39 % of patients with RA receiving biologics
take them as monotherapy [3, 10–16].
The factors that influence physicians to
prescribe biologic monotherapy, as opposed to
biologics in combination with DMARDs, in
routine clinical practice may be complex and
have not been thoroughly evaluated. In a
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retrospective cohort study, the most common
reasons for prescribing biologic monotherapy
(anti-TNFs or tocilizumab) were intolerance to
MTX, presence of contraindications to this
agent or comorbidities, discontinuation of
DMARDs due to lack of biologic efficacy, or
patient preference [17].
The aimof this studywas to further investigate
the factors thatmay influence thedecision to start
a biologic as monotherapy or in combination
with conventional DMARDs in a real-world
cohort of biologic-naive patients with RA.
METHODS
Study Population
The Corrona registry is an independent,
prospective observational cohort of patients
with RA recruited at more than 160 private and
academic practice sites across 40 states in the
United States, with more than 600 participating
rheumatologists. As of March 31, 2014, data on
approximately 39,950 patients with RA have
been collected. Corrona’s database includes
information about 285,726 patient visits and
approximately 119,298 patient-years of follow-
up observation time, with a mean time of
patient follow-up of 3.6 years (median,
2.8 years). Details of the Corrona registry
design have been previously described [18].
At each Corrona registry visit, patients and
physicians record data on disease severity and
activity, RA and other medications, adverse
events, quality of life, selected laboratory and
imaging results, and socio-demographic
information. For this study, patients with RA
who had previously received only conventional
DMARDs and were initiating their first biologic
were included in the analysis.
All patients in Corrona had previously
provided written informed consent for
participation in the registry. The Corrona
protocol was approved by the institutional
review boards of participating academic sites
and a central institutional review board for
private practice sites.
Statistical Analysis
Every biologic initiation was categorized as
monotherapy (Bio MT) or in combination with
a conventional DMARD (Bio CMB). Baseline
characteristics were compared between patients
receiving Bio MT and those receiving Bio CMB,
and included patient demographics, disease
characteristics, concurrent medications, and
history of comorbidities. In addition, reasons
for discontinuation of previously administered
conventional DMARDs were described for
patients initiating Bio MT and Bio CMB.
Demographic and educational characteristics
of prescribing physicians were also summarized.
Mixed effects logistic regression models were
estimated to examine predictors of
monotherapy in biologic-naive initiators with
the prescribing physician as a random effect.
The random effect accounted for the correlation
of treatment decision (monotherapy or
combination therapy) among patients treated
by the same physician. Potential covariates for
the multivariable models included factors based
on biologic plausibility in addition to any
patient or physician covariates that were
significantly different between Bio MT and Bio
CMB initiations in univariate comparisons
(P\0.05). Whether the biologic initiation took
place before or after the year 2006, when more
biologics became available and/or approved for
monotherapy, was included in the models to
adjust for confounding factors. After the initial
subset of significant covariates was determined,
covariates that were not significantly different
were considered for addition into the model but
Rheumatol Ther (2015) 2:85–96 87
were not significantly associated. Additionally,
covariates (such as presence of joint erosions or
low neutrophil counts) that were significantly
different in univariate comparisons between Bio
MT and Bio CMB, but resulted in a reduction of
sample size due to data availability, were
considered in separate reduced sample models
to illustrate their potential impact as sensitivity
analyses. As disease activity measures are
collinear, the choice of the measures used in
the regression models was determined using
both Akaike information criteria and Bayes
information criteria [19, 20].
The estimated physician random effects
measure the variation in rates of monotherapy
among physicians due to unmeasured
heterogeneity among physicians’ patient
populations and in physicians’ treating
patterns. A median odds ratio (MOR) was
computed as a measure to compare the impact
of variation in individual physicians’ use of
biologic agents as monotherapy compared with
the fixed effects in the model [21]. An odds ratio
(OR) was calculated for all possible pairs of
physicians’ rates of Bio MT, resulting in a
distribution of ORs for physicians from highest
rate to lowest rate of Bio MT prescription. The
median of this distribution was designated as
the MOR. The MOR can be directly computed
from the variance of the random effects and the
95 % confidence interval (CI) was calculated
from the 95 % CI of the variance. All statistical
analysis was completed using STATA, version
12.1 (StataCorp LP, College Station, TX).
RESULTS
Patient Disposition and Baseline
Characteristics
Between October 2001 and April 2012, a total of
3,923 biologic-naive patients with RA initiated a
biologic agent. Thebiologic agentwas initiated as
monotherapy in 750 patients (19.1 %) and in
combination with conventional DMARDs in
3,173 patients (80.9 %). Baseline demographics
and disease characteristics of patients receiving
Bio MT and Bio CMB are shown in Table 1.
Patients who initiated Bio MT or Bio CMB were
similar with respect to age, sex, duration of
disease, and clinical disease activity index at
baseline (Table 1). Of patients who received Bio
CMB, the majority (83.9 %) received concurrent
MTX (Table 1). Patients who initiated Bio CMB
had significantly more joint erosions, higher
swollen joint counts, and greater likelihood of
prior MTX and DMARD use compared with
patients who initiated Bio MT. In contrast, a
significantly higher proportion of patients
receiving Bio MT had a history of cancer,
hepatic events, and neutropenia compared with
patients initiating Bio CMB. The rate of Bio MT
initiation was similar before and after 2006
[19.7 % (n = 270/1,369) vs 18.8 % (n = 480/
2,554), respectively], regardless of the increased
availability of monotherapy options after 2006.
Discontinuation of Prior DMARDs
Ninety-five percent of the patients included in
this analysis had previously received
conventional DMARDs, with MTX being the
most commonly prescribed (87.9 %). The
remaining 5 % of patients were started on
biologic agents without prior use of
conventional DMARDs. Reasons for
discontinuation of prior DMARDs were
unavailable for approximately 50 % of patients.
Of patients initiating Bio MT, the most
common reasons for discontinuing any prior
DMARDs were toxicity and lack of efficacy, with
a significant proportion of discontinuations due
to patient or physician preference (Fig. 1a).
Furthermore, the most frequently reported
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Age, mean (SD), years 57.33 (13.5) 56.85 (14.7) 57.45 (13.2) 0.28
Female, % 75.86 74.42 76.19 0.32
White, % 81.55 83.56 81.08 0.13
Duration of RA, mean (SD), years 8.28 (9.3) 8.47 (9.0) 8.24 (9.3) 0.54
RF seropositivity, % 75.43 75.43 75.43 1.00
Disease activity, mean (SD)
Tender joints, 28 count 6.05 (6.8) 5.98 (7.0) 6.07 (6.8) 0.75
Swollen joints, 28 count 6.15 (6.2) 5.33 (6.0) 6.34 (6.2) \0.01
Physician global assessment 31.87 (22.1) 31.02 (22.6) 32.07 (22.0) 0.24
Patient global assessment 38.63 (27.2) 39.85 (29.1) 38.35 (26.7) 0.19
Patient pain 41.44 (29.1) 43.22 (35.3) 41.02 (27.5) 0.07
mHAQ score, mean (SD) 0.47 (0.5) 0.47 (0.5) 0.47 (0.5) 0.90
CDAI score, mean (SD) 19.27 (14.0) 18.57 (14.3) 19.43 (13.9) 0.14
Erosive disease, % 46.63 41.93 47.73 0.02
Current smoker, % 19.69 20.50 19.50 0.57
Comorbidities, %
History of MI 2.70 2.93 2.65 0.62
History of stroke 1.99 2.27 1.92 0.56
History of CVD 0.69 0.40 0.76 0.46
History of cancer 0.74 1.47 0.57 0.02
History of serious infections 1.02 1.52 0.89 0.27
History of hepatic events 0.99 2.67 0.60 \0.01
History of low platelet countsb 0.46 0.92 0.37 0.13
History of anemiac 0.08 0.00 0.10 1.00
History of lung diseased 0.46 0.80 0.38 0.13
History of low neutrophil countse 1.77 4.05 1.29 0.03
Prior DMARD use, % 95.00 85.60 97.23 \0.01
Prior MTX use, % 87.89 71.87 91.68 \0.01
Concurrent conventional DMARD use, %
MTX only – – 68.6 –
[1 DMARD (including MTX) – – 15.3 –
Leﬂunomide – – 6.5 –
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reason for discontinuing prior MTX (45.5 %),
leflunomide (46.2 %), and hydroxychloroquine
(30.4 %) was toxicity, whereas the most
frequently reported reason for discontinuing
sulfasalazine was lack of efficacy (37.2 %).
Of patients who initiated Bio CMB, toxicity
(36.6 %) was the most frequently reported
reason for discontinuing prior MTX and lack
of efficacy (31.5 %) was the most common
reason for discontinuing prior sulfasalazine;
however, reasons not related to toxicity or
efficacy (e.g., physician preference) were the
most common reasons for discontinuing
leflunomide and hydroxychloroquine (Fig. 1b).
Physician Characteristics in Prescribing
Biologic Therapy in Biologic-Naive
Patients
Physicians’ demographic and practice
characteristics were available for 157 of 247









Hydroxychloroquine – – 4.4 –
[1 DMARD (excluding MTX) – – 2.6 –
Sulfasalazine – – 1.5 –
Other DMARDs – – 1.2 –
Prescription of biologic approved
before 2006, %f
65.10 64.00 65.36 0.50
Initiation of biologic approved for
monotherapy, %
69.28 76.53 67.57 \0.01
Type of biologic initiated, %
Anti-TNF 90.95 88.93 91.43 0.03g
Non-anti-TNF 9.05 11.07 8.57
Concurrent prednisone, % 30.16 28.93 30.44 0.43
Prednisone dose, mean (SD), mg/dayh 6.4 (4.3) 7.1 (4.9) 6.3 (4.1) \0.01
anti-TNF anti-tumor necrosis factor agent, Bio CMB biologic in combination with a conventional DMARD, Bio MT
biologic monotherapy, CDAI clinical disease activity index, CVD cardiovascular disease, DMARD disease-modifying
antirheumatic drug, mHAQ modiﬁed Health Assessment Questionnaire, MI myocardial infarction,MTX methotrexate, RA
rheumatoid arthritis, RF rheumatoid factor
a P values are for comparisons between patients who initiated Bio MT vs Bio CMB
b Low platelets deﬁned as platelets\100,000/mm3
c Anemia deﬁned as hemoglobin\8 g/dL
d Lung disease uses comorbidity indicators that varied across versions: lung disease, pulmonary ﬁbrosis, or interstitial lung
disease
e Low neutrophils deﬁned as\1,000/mm3
f After 2006, more biologics became available
g P value assessed using Fisher’s exact test
h Mean (SD) prednisone dose calculated only from patients receiving prednisone with dose reported (Bio MT, n = 205;
Bio CMB, n = 912)
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The demographic characteristics of physicians
at the time of prescribing biologic therapy to
biologic-naive patients in this analysis are
presented in Table 2. Of the 157 physicians
included in the analysis with demographic
information available, the majority were male,
aged [50 years, had [19 years of experience
and worked at private sites.
Fig. 1 Reported reasons for discontinuation of prior
DMARDs in biologic-naive patients initiating a Bio MT
and b Bio CMB. Bio CMB biologic in combination with a
conventional DMARD, Bio MT biologic monotherapy,
DMARD disease-modifying antirheumatic drug, HCQ
hydroxychloroquine, LEF leﬂunomide, MTX methotrex-
ate, SSZ sulfasalazine
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Predictors of Initiating Bio MT
Three mixed effects logistic regression models
were fitted to estimate the odds for use of Bio
MT in biologic-naive patients (Table 3). Model 1
(results presented in the second column of
Table 3) represents the largest sample of
biologic-naive patients and includes covariates
such as history of comorbidities (hepatic disease
and malignancy), swollen joint counts, whether
the biologic initiated was approved for
monotherapy in the United States, whether
the treatment was initiated after 2006, and the
impact of individual physician treatment
decisions. History of hepatic events (OR 6.50;
95 % CI, 3.20–13.07), malignancies (OR 3.79;
95 % CI, 1.64–8.73), use of a biologic that was
approved for monotherapy (OR 1.47; 95 % CI,
1.20–1.81), and variation in individual
physician use of monotherapy (MOR 1.89;
95 % CI, 1.66–2.23) were all significantly
associated with higher odds of monotherapy
initiation.
Models 2 and 3 (results presented in the third
and fourth columns of Table 3, respectively)
consider additional covariates, including the
presence of erosions and history of neutropenia
in addition to some or all covariates from model
1, but result in a reduced sample size. History
of neutropenia (OR 4.89; 95 % CI, 1.16–20.59)
was associated with biologic initiation as
monotherapy in model 3.
As shown in Table 3, factors that influenced
the likelihood of initiating Bio MT in all of the
models included whether the biologic was
approved for monotherapy at the time of
prescription as well as the effect of variation in
individual physician use of monotherapy.
History of hepatic disease (models 1 and 2),
history of malignancy (models 1 and 2), and
neutropenia (model 3) also increased the odds
of a patient being prescribed Bio MT in select
analyses. Presence of erosions or whether
therapy was prescribed before or after 2006 did
not have an impact on the decision to initiate
treatment as monotherapy in any of the 3
models.
DISCUSSION
Current European League Against Rheumatism
(EULAR) and American College of
Rheumatology guidelines for the management
of RA emphasize that treatment should be a
shared decision between physicians and
patients, and should aim at reaching a target of
low disease activity or remission [1, 2].
Table 2 Characteristics of physicians from Corrona




Total physicians, Na 157
Female, % 35.0
Age, mean (SD), years 51.1 (9.2)
Years since training completed, mean (SD) 19.6 (10.3)
Years since graduation, mean (SD) 27.2 (10.8)
Site: private vs academic, %b 73.3





Physician characteristics refer to the time point of the
initiation of the biologic agent
SD standard deviation
a Total number of physicians included in the analysis with
demographic information available
b N = 247; total number of physicians included in the
analysis
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Treatment should begin with conventional
DMARDs and, if there is no response, to initiate
treatment with biologics in combination with
conventional DMARDs [1, 2]. Importantly, the
EULAR Task Force does not recommend use of
biologics as monotherapy and strongly supports
the use of all biologics in combinationwithMTX
or other conventional DMARDs [2]. While
studies with anti-TNFs have shown
adalimumab and etanercept as monotherapy
are comparable in efficacy to conventional
DMARDs, using them in combination with
conventional DMARDs is better than either
treatment alone [5–7]. The EULAR Task Force
mentions that if monotherapy must be started,
then some supportive evidence for such a
strategy exists only for tocilizumab [2].
The goal of this study was to describe the
frequency of monotherapy biologic initiation in
a real-world setting and to identify whether any
factors beyond toxicities and intolerance to
conventional DMARDs may influence the
decision to start a biologic as monotherapy. In
this US-based registry analysis, Bio MT was
common and was initiated in approximately 1
of 5 biologic-naive patients with RA initiating a
biologic agent. In previous biologics registry
and claims database studies, 12–39 % of patients
who were taking biologics did so as
monotherapy [3, 10–16]. As expected, we
identified that patients who received Bio MT
frequently had prior toxicity to conventional
DMARDs. Prior conventional DMARDs were
also commonly discontinued due to lack of
efficacy. However, reasons not related to either
toxicity or efficacy, such as physician preference
and patient preference, were frequently
reported as reasons for discontinuing prior
conventional DMARDs. In multivariate
analyses, initiation of Bio MT in this biologic-
naive population was associated with the
presence of comorbidities, including history of
hepatic disease, neutropenia, and malignancy.
In addition to the findings above, significant
variation in physician use of monotherapy
influenced the odds of initiating Bio MT in
biologic-naive patients. This was assessed by
calculating the estimated physician random
Table 3 Adjusted odds ratios for biologic monotherapy vs combination in biologic-naive patients






History of hepatic disease 6.50 (3.20–13.07) 7.49 (3.19–17.58) 5.20 (0.95–28.49)
History of malignancy 3.79 (1.64–8.73) 2.78 (1.02–7.59) 1.00 (0.19–5.40)
Swollen joint count 0.97 (0.95–0.99) 0.96 (0.95–0.98) 0.98 (0.94–1.02)
Use of biologic approved for MT 1.47 (1.20–1.81) 1.45 (1.13–1.86) 1.93 (1.08–3.43)
Initiated after 2006 0.83 (0.68–1.00) 0.79 (0.63–0.99) –
Erosions – 0.84 (0.68–1.03) 0.96 (0.62–1.49)
History of neutropenia – – 4.89 (1.16–20.59)
Random effect of individual physician’s treatment decisions 1.89 (1.66–2.23) 1.86 (1.61–2.25) 1.58 (1.23–2.72)
OR[1 implies that monotherapy is more likely
CI conﬁdence interval, MT monotherapy, OR odds ratio
a Three different models with various combinations of ﬁxed effects from independent variables described above and a
random effect of individual physician’s treatment decisions were ﬁtted
b Models were ﬁtted using available data among 3,923 previously biologic-naive patients initiating a biologic therapy
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effects, which measure the variation in rates of
monotherapy among physicians due to
unmeasured heterogeneity among physicians’
patient populations and in physicians’ treating
patterns. A possible interpretation is that some
physicians are more likely to start a biologic
agent as monotherapy for reasons other than
the ones recorded in the Corrona registry,
which include toxicity, efficacy, cost and
insurance-related reasons, or contraindication
to conventional DMARDs. Some physicians
may have prescription habits that differ from
others or their patient populations may have
characteristics that are difficult to objectively
measure; these factors may be enough to lead to
differential therapy decision making by treating
rheumatologists.
This study analyzed initiations of only the
first biologics for each participating patient;
however, as RA is a chronic disease, treatment
strategies are dynamic in nature and patients
may have monotherapy treatment regimens
prescribed intermittently alternating with
combination regimens. The reasons patients
initiate monotherapy with different biologics
may vary and be biologic specific, including
preference for a particular route or frequency of
administration. Additionally, the patient-
physician decision-making process often
involves a complex dialog, and there may be
reasons for changing from DMARDs to biologics
that may not be possible to be fully described or
captured.
CONCLUSION
In conclusion, initiating biologic monotherapy
in the biologic-naive population of this study
was significantly influenced by variation in
physician use of monotherapy, as well as
whether the biologic was approved for
monotherapy in the United States and history
of hepatic disease, neutropenia, or malignancy.
Further prospective analyses will follow
prescription patterns to compare efficacy
outcomes of patients initiating Bio MT with
those initiating Bio CMB and evaluate whether
Bio MT is associated with less toxicity.
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